You are here: Acridine-raw-material NewsViews

Slow the progression of Alzheimer's disease, potential drug candidates

Alzheimer's disease (AD) is an insidious, progressive and irreversible brain disorder with a high incidence of people over the age of 65. Current AD therapeutic goal is to maintain the body functions and the ability to slow down or delay the symptoms at the same time. Mild to moderate AD drugs include acetylcholinesterase inhibitors donepezil, rivastigmine and galantamine. Donepezil is also used to treat moderate to severe AD, alone or in combination with N- methyl -D- aspartate (NMDA) receptor antagonist memantine in combination. These neurotransmitters regulate drugs can temporarily improve symptoms, but patients will experience a gradual deterioration of cognitive ability, as well as mental illness, restlessness, depression and sleep disorders.
AD therapy is currently the main focus is the development of new drugs to inhibit Aβ aggregation and Aβ clearance. Some target Aβ or tau protein immunotherapy new drugs being deeply Ⅲ clinical trials, small molecule inhibitors of BACE1 also began on a large scale Ⅲ clinical trials.
AD verify the efficacy of the therapeutic agent is very difficult, many in advanced clinical trials of drug candidates failed to meet the primary endpoint, such as AN1792 and bapineuzumab. The researchers are turning their focus from mild to moderate AD, steering precursor or mild AD, slow the progression hoping to find potential drug candidates.